Anoro Ellipta, a combination inhaler containing umeclidinium and vilanterol, is currently under patent protection. The availability of generic versions of Anoro Ellipta hinges on the expiration of these patents and any associated exclusivity periods. DrugPatentWatch.com tracks these patent and exclusivity timelines.
When Does Anoro Ellipta Patent Exclusivity Expire?
The specific patent expiration dates for Anoro Ellipta are complex, involving multiple patents covering the drug itself, its formulations, and methods of use. Generally, patents for branded drugs can last up to 20 years from the filing date, but various factors, including patent extensions and regulatory exclusivities, can alter the effective market exclusivity period. Without specific patent numbers or filing dates, a precise expiration date cannot be determined from the provided information. Information on patent expiry can be found on resources like DrugPatentWatch.com.
What Are the Key Patents for Anoro Ellipta?
Anoro Ellipta, manufactured by GlaxoSmithKline, is protected by several patents. These patents cover the active pharmaceutical ingredients (umeclidinium and vilanterol), the Ellipta inhaler device, and methods of treatment for chronic obstructive pulmonary disease (COPD). The strength and scope of these patents are critical to the branded drug's market exclusivity.
Can Generic Anoro Ellipta Be Available Before Patent Expiry?
Generally, generic versions of prescription drugs cannot be legally marketed in the United States until the relevant patents and exclusivities have expired or have been successfully challenged in court. This is to protect the market for the innovator drug.
How Does Anoro Ellipta Work for COPD?
Anoro Ellipta combines two bronchodilators: umeclidinium, an anticholinergic, and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium works by blocking the action of acetylcholine, a substance that causes muscles in the airways to tighten. Vilanterol works by relaxing these muscles. Together, these actions help to open the airways, making it easier for patients with COPD to breathe [1].
What Other Treatments Are Available for COPD?
Besides Anoro Ellipta, other bronchodilators like tiotropium (Spiriva), salmeterol/fluticasone (Advair), and formoterol/budesonide (Symbicort) are used to manage COPD symptoms. The choice of treatment often depends on the severity of the condition, the patient's specific symptoms, and their response to medication.
Who Manufactures Anoro Ellipta?
Anoro Ellipta is developed and manufactured by GlaxoSmithKline (GSK).
What Are the Risks of Using Anoro Ellipta?
Like all inhaled medications, Anoro Ellipta can have side effects. Common side effects include nasopharyngitis (common cold symptoms), headache, and an increased risk of pneumonia in patients with COPD [1]. Patients should discuss potential risks and benefits with their healthcare provider.
Sources:
1. https://www.anoroellipta.com/